Skip to main content

Prevymis FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 4, 2024.

FDA Approved: Yes (First approved November 8, 2017)
Brand name: Prevymis
Generic name: letermovir
Dosage form: Tablets, Oral Pellets and Injection
Company: Merck
Treatment for: CMV Prophylaxis

Prevymis (letermovir) is a CMV DNA terminase complex inhibitor used for the prophylaxis of cytomegalovirus (CMV) infection.

Development timeline for Prevymis

DateArticle
Jun  6, 2023Approval U.S. FDA Approves New Indication for Merck’s Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Nov  9, 2017Approval FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.